![FDA Rejects Merck-Daiichi Lung Cancer Drug](/content/images/size/w600/2024/06/febc7fca-469a-4fb0-9c31-5d6a3837e970.png)
Health
FDA Rejects Merck-Daiichi Lung Cancer Drug
The U.S. Food and Drug Administration (FDA) has declined to approve the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate developed by Merck & Co. Inc. and Daiichi Sankyo, intended for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The decision